This is a Phase II, randomized, double-blind, placebo-controlled multicenter stu dy to evaluate the efficacy and safety of rontalizumab compared with placebo in patients with moderately to severely active systemic lupus erythematosus (SLE). The study will enroll approximately 210 patients at up to 100 sites in North Ame rica, Latin America, and Europe.